HSTOQ (Histogen) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2023)


HSTOQ Histogen Inc HSTOQ
12 GF Score
Price $0.00
View Full Analysis

What is Histogen LT-Debt-to-Total-Asset?

Histogen HSTOQ +316.67% 12 LT-Debt-to-Total-Asset is 0.00 as of Sep. 2023. GuruFocus rates HSTOQ with a GF Score™ of 12/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Histogen's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.00.

Histogen's long-term debt to total assets ratio declined from Sep. 2022 (0.20) to Sep. 2023 (0.00). It may suggest that Histogen is progressively becoming less dependent on debt to grow their business.

Histogen  (OTCPK:HSTOQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Histogen LT-Debt-to-Total-Asset Related Terms

Histogen LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Histogen's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Histogen LT-Debt-to-Total-Asset Chart

Histogen Annual Data
Trend Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
0.01 0.35 0.17 0.23

Histogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.23 0.27 0.31 0.00
HSTOQ
12GF Score
Histogen Inc HSTOQ
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Histogen LT-Debt-to-Total-Asset Calculation

Histogen's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=4.384/19.073
=0.23

Histogen's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )/Total Assets (Q: Sep. 2023 )
=0/5.817
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Histogen (HSTOQ) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Histogen and its competitors.
Is Histogen's LT-Debt-to-Total-Asset too high?
Histogen's current LT-Debt-to-Total-Asset is 0.00. Overall, Histogen has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Histogen's LT-Debt-to-Total-Asset compare to GLMD and BLCM?
Histogen's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Histogen and its competitors. Histogen's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Histogen stock overvalued right now?
Histogen (HSTOQ) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Histogen's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Histogen (HSTOQ), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Histogen Business Description

Address 10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
12GF Score

Get the complete analysis for HSTOQ

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price